I can understand the IHL-42X landscape can be a little confusing with two pending trials
IHL-42x will be studied in two separate trials done in parallel.
>> BA/BE study in South Australia at the C-MAX facility has received HREC approval today to commence. >> Phase 2/3 Trial in Europe & USA with up to 400 participants over 45 trial locations https://stocknessmonster.com/announcements/ihl.asx-3A620063/(Latest trial update) Each trial is independent of the other, so HREC approval today for the BA/BE study.
If the HREC approval was not granted/declined it would have created some uncertainty, as the BA/BE study will be instrumental in the longer term. As @kingkev said it's another box ticked on the journey.
The BOD is getting all their ducks aligned for IHL-42X, we are expecting the IND filing for IHL-42x (phase 2/3 Trial - under FDA supervision) to eventuate in the coming days/weeks and this BA/BE study will complement and support the eventual NDA application once the phase 2/3 Trial is completed.